Debiopharm Group

vorige Seite Seite 1 von 2 nächste Seite

Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer

Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer

OTE0001
07.06.2016 17:18
 

FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation …

OTE0002
02.06.2016 09:03
 

Debiopharm International SA to Present the Latest Findings on Debio 1450 at ECCMID

Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450

OTE0001
08.04.2016 09:02
 

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.

Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for …

OTE0002
04.03.2016 09:03
 

Debiopharm International SA and EORTC Announce a Collaboration to Investigate Triptorelin for Treatment of Salivary Gland Cancers

Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month …

OTE0005
13.01.2016 16:03
 

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty

Arbor Pharmaceuticals to commercialize triptorelin in sustained-release formulation for the orphan indication central precocious puberty

OTE0003
11.01.2016 15:32
 

EMA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug …

OTE0002
08.12.2015 09:03
 

United Laboratories Inc. and Debiopharm International SA Announce the Launch of Pamorelin® LA in the Philippines

Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines

OTE0001
07.12.2015 09:05
 

Debiopharm International SA's Partner Yakult Honsha Co, Ltd. Announces Elplat® Approbation in Gastric Cancer in Japan

Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, is proud to congratulate its partner Yakult's commitment in obtaining approval for a …

OTE0001
24.11.2015 09:02
 

Die Japanische Krebsgesellschaft und die Debiopharm Group geben die Gewinner des JCA-Mauvernay Awards 2015 bekannt

Der "JCA-Mauvernay Award 2015" geht an Dr. Yutaka Kondo und Dr. Junko Takita  

OTS0015
09.10.2015 09:03
 

Debiopharm International SA und Solid Biosciences, LLC, kündigen Partnerschaft an, um die Anwendung von Alisporivir (Debio 025) bei Muskeldystrophie zu erforschen

Debiopharm startet zusammen mit Solid Biosciences, einem auf DMD spezialisiertes Biotech-Unternehmen, präklinische Tierstudien für Muskeldystrophie Typ Duchenne (DMD).  

OTS0020
08.09.2015 09:03
 

Debiopharm International SA Acquires FibroTrap Sample Processing Technology from Spinomix

Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, and Spinomix, a Swiss technology platform company providing innovative sample …

OTE0005
16.06.2015 14:03
 

Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections

One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID

OTE0001
23.04.2015 08:33
 
vorige Seite nächste Seite